## Company Overview

**Industry Sector:** Targeted radiopharmaceuticals

**Company Overview:** AlphaMed Inc. is a privately held “c” corp that develops technology enabling the company to produce scarce radioisotopes that have shown promise in cancer therapy. It develops novel therapies with researchers that have molecules that bind to receptors overexpressed in cancer tumors. AlphaMed conducts preclinical tests to demonstrate efficacy in animals and brings therapies to clinical trials to demonstrate safety and efficacy in people. It partners with pharmaceutical companies for assistance in regulatory affairs and down stream funding and commercialization. The product closest to clinical trials is the targeted melanoma therapy. Preclinical research is also being conducted on breast, ovary, lung and prostate cancers.

**Target Market(s):** Oncology – imaging and targeted radiotherapy with a special focus on developing a cure for the targeted diseases.

## Key Value Drivers

**Technology**: Targeted melanoma therapy was demonstrated in animal studies. Half the animals receiving the highest dose showed a complete cure. Every animal receiving even the lowest dose showed life extension. An imaging partner to the therapeutic that would be used for treatment planning was developed and demonstrated.

**Competitive Advantage:** There is no effective therapy for advanced melanoma. The only FDA approved therapy is Interleukin-2 which is effective in a very small patient population and has severe side effects that restrict it to otherwise healthy patients. Other therapies in clinical trials have shown life extension, no therapy has shown a cure for this disease. AlphaMed’s therapy targets receptors that are overexpressed in approximately 80% of melanomas and represents on the order of $450 million in annual sales for both the treatment planning and therapeutic products.

**Plan & Strategy:** Seeking a strategic partner to assist in regulatory affairs, clinical trials, and commercialization

*Technology funded by the NCI and being commercialized under the NIH-CAP*

## Management

**Two founders operating a virtual company running multiple projects**

**Leadership:**
- Richard F. Testa, President and CEO
- Herbert A. Moore, Vice President Research

**Collaborators from the following leading institutions and their role:**
- Pacific Northwest National Laboratory – isotope development
- Argonne National Laboratory – isotope development
- University of Missouri-Columbia – targeting molecule
- Rensselaer Polytechnic Institute – isotope development
- Walter Reed Army Medical Center – clinical trial site
- National Naval Medical Center – clinical trial site
- Stanford University Medical Center – clinical trial site
- VA/UMo Hospital, Columbia, MO – clinical trial site
- Russia Military Medical Academy – clinical trial site
- Rush Medical Center, Chicago – clinical trial site
- Industry consultants – clinical trials support

## Product Development

**Advanced Melanoma** – Treatment planning and therapeutic drugs in preclinical animal tests. Expect to commence clinical trials in 12 to 18 months

**Competitive Edge**
- An exclusive option to a patent license for the targeting molecule
- Know-how to produce the isotope and radiolabel the compound
- The sole producer of the isotope
- Additional IP being developed

**Breast, Ovary, Lung, and Prostate cancers in preclinical research**

**Peptide targeting molecule, binding ligands, and radioisotopes that include imaging and therapeutic isotopes of the same element.** Pb-203 can be imaged with a standard SPECT camera and used for treatment planning for the Pb-212 labeled peptide that is used for therapy. Other scarce and promising radioisotopes that can be produced in quantities to support commercialization of radiopharmaceuticals include Ra-224, Pb-211, Cu-67 and Lu-177 for therapy and In-111 and I-123 for imaging.